How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

236 results for

Eslicarbazepine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action (Full text)

Eslicarbazepine acetate for the treatment of focal epilepsy: an update on its proposed mechanisms of action Eslicarbazepine acetate (ESL) is a once daily antiepileptic drug (AED) approved by the European Medicines Agency (EMA), the Food and Drug Administration (FDA) and Health Canada as an adjunctive therapy in adults with partial-onset seizures (POS). In humans and in relevant animal laboratory species, ESL undergoes extensive first pass hydrolysis to its major active metabolite (...) eslicarbazepine that represents ∼95% of circulating active moieties. ESL and eslicarbazepine showed anticonvulsant activity in animal models. ESL may not only suppress seizure activity but may also inhibit the generation of a hyperexcitable network. Data reviewed here suggest that ESL and eslicarbazepine demonstrated the following in animal models: (1) the selectivity of interaction with the inactive state of the voltage-gated sodium channel (VGSC), (2) reduction in VGSC availability through enhancement

2015 Pharmacology research & perspectives

62. Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. (Full text)

Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a historical-control phase III study. Eslicarbazepine acetate (ESL, Aptiom®) is a once-daily (QD) anticonvulsant, approved as adjunctive treatment of partial-onset seizures (POS). It is extensively converted after oral administration to eslicarbazepine, and is believed to exert its effect through inhibition of voltage-gated sodium channels. The possible role of ESL

2015 BMC neurology Controlled trial quality: predicted high

63. Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. (Full text)

Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. To evaluate the efficacy and safety of adjunctive eslicarbazepine acetate (ESL) in patients with refractory partial-onset seizures.This randomized, placebo-controlled, double-blind, parallel-group, phase III study was conducted at 173 centers in 19 countries, including the United States and Canada. Eligible patients were

2015 Epilepsia Controlled trial quality: predicted high

64. Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. (PubMed)

Assessment of the efficacy and safety of eslicarbazepine acetate in acute mania and prevention of recurrence: Experience from multicentre, double-blind, randomised phase II clinical studies in patients with bipolar disorder I. Eslicarbazepine acetate (ESL) is an anticonvulsant approved as an adjunctive therapy in adults with partial-onset seizures.To evaluate the efficacy, safety and tolerability of ESL in the treatment of acute mania and prevention of recurrence in bipolar disorder I.Two 3

2015 Journal of Affective Disorders Controlled trial quality: predicted high

65. Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine

Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one (...) or more studies before adding more. Disposition of Eslicarbazepine Acetate and Its Metabolites S-licarbazepine and R-licarbazepine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02281591 Recruitment Status : Completed First Posted : November 3, 2014 Results First Posted : December 3, 2014 Last Update

2014 Clinical Trials

66. Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation

Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number (...) of saved studies (100). Please remove one or more studies before adding more. Single Dose Crossover Comparative Bioavailability Study of Eslicarbazepine Acetate Versus To-be-marketed Formulation The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283840 Recruitment Status : Completed First Posted

2014 Clinical Trials

67. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283827 Recruitment Status : Completed First Posted : November 5, 2014 Results First Posted : December 18, 2014 Last Update Posted : December 18, 2014 Sponsor: Bial

2014 Clinical Trials

68. A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283814 Recruitment Status : Completed First Posted : November 5, 2014 Results First Posted : December 22, 2014 Last Update Posted : December 22, 2014

2014 Clinical Trials

69. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine.

Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Lamotrigine. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283801 Recruitment Status : Completed First Posted : November 5, 2014 Last Update Posted : November 5, 2014 Sponsor: Bial - Portela C S.A. Information

2014 Clinical Trials

70. Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization

Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding (...) more. Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02283788 Recruitment Status : Completed First Posted : November 5, 2014 Results First Posted : December 22, 2014 Last Update Posted : December 22, 2014 Sponsor

2014 Clinical Trials

71. Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate

Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Food (...) Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02288312 Recruitment Status : Completed First Posted : November 11, 2014 Results First Posted : January 8, 2015 Last Update Posted : January 8, 2015 Sponsor: Bial - Portela C S.A

2014 Clinical Trials

72. Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate

Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Comparative Bioavailability Study of Two Different Sources of Eslicarbazepine Acetate The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02284880 Recruitment Status : Completed First Posted : November 6, 2014 Results First Posted : January 12, 2015 Last Update Posted : January 12, 2015

2014 Clinical Trials

73. Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine

Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Pharmacokinetic Interaction Study Between Eslicarbazepine Acetate and Carbamazepine The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02284854 Recruitment Status : Completed First Posted : November 6, 2014 Results First Posted : January 8, 2015 Last Update Posted : January 8, 2015 Sponsor

2014 Clinical Trials

74. Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function

Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Effects of Eslicarbazepine Acetate (BIA 2-093) on Cognition and Psychomotor Function The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02284828 Recruitment Status : Completed First Posted : November 6, 2014 Results First Posted : December 10, 2014 Last Update Posted : December 10, 2014

2014 Clinical Trials

75. Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects. (Full text)

Bioequivalence of eslicarbazepine acetate from two different sources of its active product ingredient in healthy subjects. To compare the bioavailability (BA) and pharmacokinetic (PK) properties and to demonstrate the bioequivalence (BE) between two active product ingredient (API) sources of eslicarbazepine acetate (ESL) in healthy volunteers.Forty healthy male and female subjects aged 18-40 years were randomized to treatment with 400 or 800 mg ESL marketed (MF) formulation [current active

2013 Drugs in R&D Controlled trial quality: uncertain

76. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. (PubMed)

Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. To investigate the effect of once-daily (QD) eslicarbazepine acetate (ESL) 800 mg and 1,200 mg administration on pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive (OC) in women of childbearing potential.Two two-way, crossover, two-period, randomized, open-label studies were performed in 20 healthy female subjects, each

2013 Epilepsy research Controlled trial quality: uncertain

77. Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. (PubMed)

Effect of repeated administration of eslicarbazepine acetate on the pharmacokinetics of simvastatin in healthy subjects. To investigate the effect of eslicarbazepine acetate (ESL) on the pharmacokinetics of simvastatin (SMV), a known CYP3A4 substrate, in healthy subjects.Single centre, two-way cross-over, randomized, open-label study in 24 healthy volunteers. The volunteers received an oral single-dose of SMV 80mg on two occasions (once administered alone and once after treatment with an oral

2013 Epilepsy research Controlled trial quality: uncertain

78. Design of the epos study: an open-label, multicentre, non-interventional study to evaluate eslicarbazepine acetate as adjunctive treatment to one baseline antiepileptic drug in adults with partial-onset seizures. (PubMed)

Design of the epos study: an open-label, multicentre, non-interventional study to evaluate eslicarbazepine acetate as adjunctive treatment to one baseline antiepileptic drug in adults with partial-onset seizures.

2013 Neurosurgery and Psychiatry

79. Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: bia-2093-301 study. (PubMed)

Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: bia-2093-301 study.

2013 Neurosurgery and Psychiatry

80. Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. (Full text)

Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers. Investigate the pharmacokinetics of once-daily (QD; 900 mg) and twice-daily (BID; 450 mg) regimens of eslicarbazepine acetate (ESL) and BID (450 mg) regimen of oxcarbazepine (OXC) at steady state in healthy volunteers.Single-center, open-label, randomized, three-way (n = 12) crossover studies in healthy volunteers.Mean eslicarbazepine Cmax,ss (in μm) following ESL QD (87.3 (...) ) was 33.3% higher (p < 0.05) compared to ESL BID (65.5) and 82.1% higher (p < 0.05) compared to OXC BID (48.0). The mean area under the curve (AUC)ss,0-τ (in μmol h/L) following the last dose of an 8-day repeated dosing was 1156.3, 1117.6, and 968.4 for ESL QD, ESL BID, and OXC BID, respectively. The ratio eslicarbazepine plasma exposure (μmol h/L) to ESL daily-dose (μmol) was 0.381 (1156.3:3037.3), 0.368 (1117.6:3037.3), and 0.271 (968.4:3567.6) for ESL-QD, ESL-BID, and OXC-BID, respectively, which

2013 Epilepsia Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>